Skip to content
234234234UUU

Drawing based on the label description. No photo yet.

“Valsartan Tablets USP, 160 mg are yellow, almond-shaped, film-coated tablets, debossed with "234" on one side of the tablet and "U" on other side of the tablet”

U 234 pill

Pill with imprint U 234 is yellow, tear, 13 mm and has been identified as Valsartan 160 mg. It is used for high blood pressure, heart failure and a weak heart. It is supplied by Unichem Pharmaceuticals (Usa), Inc.

Valsartan 160 mg

Imprint
U 234
Strength
160 mg
Used for
High blood pressure, heart failure and a weak heart
Color
Yellow
Shape
Tear
Size
13 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Unichem Pharmaceuticals (Usa), Inc
Drug class
ARB (blood pressure medicine)
NDC
29300-234, 29300-234-13, 29300-234-19, 29300-234-10

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Valsartan pills and guides

What is Valsartan used for?

Valsartan is used for high blood pressure, heart failure, a weak heart and kidney disease from diabetes.

Medicine type
ARB (blood pressure medicine)
Official uses from the US prescribing label

1.1 Hypertension

Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and pediatric patients one year of age and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Valsartan tablets may be used alone or in combination with other antihypertensive agents.

1.2 Heart Failure

Valsartan tablets are indicated to reduce the risk of hospitalization for heart failure in adult patients with heart failure (NYHA class II-IV). There is no evidence that valsartan tablets provides added benefits when it is used with an adequate dose of an angiotensin converting enzyme (ACE) inhibitor.

1.3 Post-Myocardial Infarction

In clinically stable adult patients with left ventricular failure or left ventricular dysfunction following myocardial infarction, valsartan tablet is indicated to reduce the risk of cardiovascular mortality.

From the FDA-approved label on DailyMed (published Sep 24, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows 234 and the other side shows U.
  • It is yellow, tear, 13 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Valsartan

Inactive: Cellulose, Microcrystalline, Crospovidone, Ferric Oxide Yellow, Hypromellose 2910 (5 Mpa.s), Lactose Monohydrate, Magnesium Stearate, Polyethylene Glycol 800, Povidone K30, Silicon Dioxide, Sodium Lauryl Sulfate, Titanium Dioxide

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Valsartan pills